HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ --
Sirnaomics Ltd. (the "
Company", together with its subsidiaries, the "
Group" or "
Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, announced that the Company has entered into a subscription agreement with Dr. Poon Hung Fai ("Dr. Poon"), the subscriber. Dr. Poon intends to subscribe for 17,527,696 subscription shares at a subs